Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

What Should You Avoid Before a PSA Test?

Latest Prostate Cancer News and Research

New 3D tissue imaging technique enhances thyroid tumor analysis

Empa researchers have developed a new 3D tissue analysis for thyroid tumors. This special X-ray technique uses artificial intelligence to enable faster and more precise diagnoses.

21 Feb 2025

Vitamin E significantly improves liver health in MASH patients, new study finds

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in patients with MASH, with no major safety concerns reported.

19 Feb 2025

Inflammation and metabolic syndrome contribute to prostate enlargement in aging men

A new research paper was published by Aging (Aging-US) on January 6, 2025, in Volume 17, Issue 1, titled "The profile of oxidative stress markers (arachidonic and linoleic acid derivatives) in patients with benign prostatic hyperplasia in relation to metabolic syndrome."

19 Feb 2025

Study reveals key genetic clues for prostate cancer progression

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

18 Feb 2025

Globally prostate and testicular cancer rates climb, but mortality is falling

New research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access shape the future of prostate and testicular cancer outcomes.

12 Feb 2025

Engineered fat cells starve tumors and prevent cancer growth

Scientists transformed energy-storing white fat cells into calorie-burning 'beige' fat. Once implanted, they outcompeted tumors for resources, beating back five different types of cancer in lab experiments.

4 Feb 2025

Prostate cancer incidence rises in California following screening guideline change

Following a change in screening guidelines, the incidence went up across the state, even more than it has nationally.

3 Feb 2025

At-home urine test shows high accuracy for prostate cancer screening

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancer screening is highly accurate.

3 Feb 2025

Early side effects of radiation may increase long-term risk for prostate cancer patients

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.

31 Jan 2025

PROTAC technology offers hope for treating castration-resistant prostate cancer

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

30 Jan 2025

Climate change is pushing up rates of kidney disease and urological cancers

Climate change is increasing the risk of urological diseases, including cancer and kidney conditions, while urological healthcare itself contributes to environmental harm through high carbon emissions.

29 Jan 2025

New urine test shows promise for prostate cancer screening

Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies.

28 Jan 2025

Inherited gene mutation found to increase prostate cancer risk

A study of men with a family history of prostate cancer has discovered an inherited form of prostate cancer.

28 Jan 2025

Developmental epigenetic changes could shape cancer risk later in life

A person's lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists.

27 Jan 2025

Study highlights potential of genomic tests for early stage prostate cancer

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions about how to treat patients with early stage prostate cancer.

24 Jan 2025

OncoAssure announces clinical validation of prostate cancer test

OncoAssure Ltd, an Irish medical diagnostic company, today announced the publication of new data, in the British Journal of Urology International Compass (BJUI Compass), which demonstrates the clinical validation of OncoAssure Prostate, a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection.

21 Jan 2025

Expert consensus provides unified framework for prostate cancer care in China

While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level evidence on several aspects of patient care.

20 Jan 2025

Exploring the use of genomic classifier tests in prostate cancer risk stratification

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for better data on their cost-effectiveness, clinical utility, and their impact on racial and ethnic groups, particularly Black men.

20 Jan 2025

New resource from NCCN offers guidance on hereditary cancer risk

Today, the National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers-published a new resource to inform people about the latest recommendations around hereditary and familial cancer risk.

16 Jan 2025

NCCN global meeting focuses on cancer care in the MENA region

The National Comprehensive Cancer Network (NCCN)-a global not-for-profit alliance of leading cancer centers-is taking part in a two-day meeting at the Middle East North Africa (MENA)-NCCN Regional Coordinating Center, beginning today.

11 Jan 2025